Poly Medicure

Poly Medicure Ltd. completed a block trade on the National Stock Exchange worth Rs. 23.27 crores. The transaction involved approximately 116,048 shares at a price of Rs. 2,004.90 per share.

Poly Medicure Limited acquired 90% of PendraCare Group, a Netherlands-based interventional cardiology company, for EUR 11 million equity consideration plus EUR 3.2 million inter-group loan liabilities. The acquisition includes taking over EUR 2.9 million net debt, valuing the deal at 1.8x EV/revenue and 13x EV/EBITDA. PendraCare generated EUR 9.9 million revenue and EUR 1.4 million EBITDA in calendar year 2024, with 74% gross margins. The company operates FDA-approved facilities in Netherlands with capacity for 1.5 million units annually, currently producing 700,000-800,000 units. PendraCare specializes in guiding and diagnostic catheters for interventional cardiology, serving 35+ countries through 50+ distributor relationships. Poly Medicure expects EUR 3-4 million incremental EBITDA synergies over 3-4 years and projects PendraCare could reach EUR 25 million revenue by 2030. The remaining 10% stake held by CEO Sander Hartman will be acquired in 2030 based on 2029 EBITDA performance. The acquisition supports Poly Medicure's global cardiology expansion strategy and provides European manufacturing footprint with regulatory approvals.

Poly Medicure Limited has announced September 18, 2025 as the record date for a final dividend of ₹3.50 per equity share for FY 2024-25. The company's share transfer books will remain closed from September 19 to September 25, 2025. The dividend is subject to shareholder approval at the Annual General Meeting scheduled for September 25, 2025. The dividend applies to equity shares with a face value of ₹5 each.